May 7, 2020 / 12:01 PM / 22 days ago

BRIEF-Ascentage Pharma's Core Drug Candidate HQP1351 Granted Fast Track Designation By FDA

May 7 (Reuters) - Ascentage Pharma Group International :

* ASCENTAGE PHARMA’S CORE DRUG CANDIDATE HQP1351 GRANTED FAST TRACK DESIGNATION BY THE US FDA, MARKING ANOTHER MILESTONE IN ITS DEVELOPMENT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below